This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Valeant Talks Takeover of Medicis: Report

ONTARIO, Canada ( TheStreet) -- Valeant Pharmaceuticals (VRX - Get Report), the Canadian drug company, may be interested in buying Medicis Pharmaceutical (MRX), according to a report.

Medicis makes dermatological and aesthetic pharmaceutical products. It has a market capitalization of about $2.1 billion.

Valeant has been hunting for acquisitions since it lost out in its bid to acquire Cephalon (CEPH), which was sold in May for $6.2 billion to Teva Pharmaceutical (TEVA - Get Report).

Valeant reportedly also has approached Swedish specialty drug maker Meda AB about a takeover.

Valeant's approach for Medicis comes amid an investigation into death of the girlfriend of Medicis's founder and chief executive, Jonah Shacknai, The Wall Street Journal reported. Since the girlfriend's death at Shacknai's home in July, Medicis shares have been underperforming the broader market, leaving the company vulnerable to a takeover approach, people familiar with the matter told the newspaper.

Shares of Medicis finished almost 5% higher Monday to $33.63 as reports surfaced about the company's possible sale.

-- Written by Joseph Woelfel

>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to:

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRX $0.00 0.00%
TEVA $63.47 0.00%
VRX $87.09 0.00%
AAPL $117.81 0.00%
FB $105.45 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs